Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study
Alex Y. Chang(Cornell University), Nick Thatcher(The Christie Hospital), Purvish M. Parikh(Tata Memorial Hospital), Sumitra Thongprasert(Chiang Mai University), Claire Watkins(AstraZeneca (United Kingdom)), Eng Huat Tan(National Cancer Centre Singapore), N. Botwood(AstraZeneca (United Kingdom)), Chao‐Jung Tsao(Chi Mei Medical Center), Domingo Ganzon, Reury-Perng Perng(Taipei Veterans General Hospital)
Cited by 129
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2006|705